- Home
- NMFC vs DYN Comparison
NMFC vs DYN Comparison
Compare NMFC & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMFC
- DYN
- Stock Information
- Founded
- NMFC 2010
- DYN 1984
- Country
- NMFC United States
- DYN United States
- Employees
- NMFC N/A
- DYN N/A
- Industry
- NMFC Finance/Investors Services
- DYN Medicinal Chemicals and Botanical Products
- Sector
- NMFC Finance
- DYN Health Care
- Exchange
- NMFC Nasdaq
- DYN Nasdaq
- Market Cap
- NMFC 1.2B
- DYN 1.2B
- IPO Year
- NMFC 2011
- DYN 2020
- Fundamental
- Price
- NMFC $10.59
- DYN $9.95
- Analyst Decision
- NMFC Hold
- DYN Strong Buy
- Analyst Count
- NMFC 3
- DYN 15
- Target Price
- NMFC $11.00
- DYN $43.07
- AVG Volume (30 Days)
- NMFC 366.7K
- DYN 3.2M
- Earning Date
- NMFC 08-04-2025
- DYN 08-11-2025
- Dividend Yield
- NMFC 12.38%
- DYN N/A
- EPS Growth
- NMFC N/A
- DYN N/A
- EPS
- NMFC 0.99
- DYN N/A
- Revenue
- NMFC $366,773,000.00
- DYN N/A
- Revenue This Year
- NMFC N/A
- DYN N/A
- Revenue Next Year
- NMFC N/A
- DYN N/A
- P/E Ratio
- NMFC $10.69
- DYN N/A
- Revenue Growth
- NMFC N/A
- DYN N/A
- 52 Week Low
- NMFC $8.84
- DYN $6.36
- 52 Week High
- NMFC $12.55
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- NMFC 47.99
- DYN 52.19
- Support Level
- NMFC $10.56
- DYN $8.95
- Resistance Level
- NMFC $10.78
- DYN $9.58
- Average True Range (ATR)
- NMFC 0.14
- DYN 0.58
- MACD
- NMFC -0.01
- DYN 0.22
- Stochastic Oscillator
- NMFC 8.82
- DYN 85.89
About NMFC New Mountain Finance Corporation
New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.